

ONCOLOGY CLINICAL NOTE

Patient Name: Robert Williams

Date of Birth: November 8, 1972 (Age: 53)

Date of Note: November 18, 2025

Diagnosis: Malignant neoplasm of prostate (ICD-10: C61)

HISTORY OF PRESENT ILLNESS

Mr. Williams is a 53-year-old male with a history of prostate cancer (C61). He has been managed with Androgen Deprivation Therapy (ADT). He presents today for follow-up and review of recent laboratory indices to assess disease stability.

LABORATORY & BIOMARKER RESULTS

Recent serum studies were obtained to evaluate testosterone suppression and Prostate-Specific Antigen (PSA) trends. The results are summarized below:

Biomarker / Test	Result	Clinical Interpretation
Serum Testosterone	<50 ng/dL	Castrate Level. Effective suppression of testosterone achieved via ADT.
PSA	Rising	Biochemical Progression. Increasing PSA despite castrate levels of testosterone indicates progression of disease.

ASSESSMENT

The patient demonstrates evidence of disease progression (rising PSA) in the setting of effective androgen deprivation (testosterone <50 ng/dL). This clinical picture is consistent with castration-resistant prostate cancer (CRPC). Escalation of therapy is warranted.

TREATMENT PLAN

1. Pharmacotherapy

- **Initiate Enzalutamide:** Start oral androgen receptor signaling inhibitor to address disease progression.

- **Continue ADT:** Maintain concurrent LHRH agonist/antagonist therapy to sustain castrate testosterone levels.

2. Monitoring & Follow-up

- **Laboratory Surveillance:** Monitor PSA and serum testosterone levels regularly to evaluate response to enzalutamide.
- **Safety Monitoring:** Assess for fatigue, blood pressure changes, and other potential side effects of anti-androgen therapy.

3. Administrative & Coverage

- **Insurance Provider:** BlueCross
- **Policy Number:** INS11223
- **Status:** Active (Coverage verified June 2024 – May 2025)
- **Action:** Initiate prior authorization for specialty pharmacy dispensing of enzalutamide.

Electronically Signed By:

[Provider Name, MD/DO]

Department of Oncology